Once the glucose is replaced with galactose in growth media, GBM cells were substantially more resistant to the cytotoxic effects of the aurora kinase A inhibitor, alisertib, which strongly suggest that aurora kinase A inhibition is more potent in highly glycolytic contexts (Table 1). The gene discussed is AURKA; the disease is glioblastoma.